MARINUS PHARMACEUTICALS INC's ticker is and the CUSIP is 56854Q200. A total of 89 filers reported holding MARINUS PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.11 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $36,555 | -23.8% | 4,541 | +2.8% | 0.00% | – |
| Q2 2023 | $47,994 | -21.5% | 4,419 | -50.2% | 0.00% | – |
| Q1 2023 | $61,176 | +6789.2% | 8,866 | +3875.8% | 0.00% | – |
| Q4 2022 | $888 | -99.9% | 223 | -99.9% | 0.00% | – |
| Q3 2022 | $1,668,000 | +37.3% | 250,867 | -0.1% | 0.00% | – |
| Q2 2022 | $1,215,000 | -58.5% | 251,095 | -19.9% | 0.00% | – |
| Q1 2022 | $2,929,000 | -40.0% | 313,282 | -23.8% | 0.00% | – |
| Q4 2021 | $4,885,000 | -9.6% | 411,165 | -13.4% | 0.00% | – |
| Q3 2021 | $5,403,000 | -36.6% | 474,790 | +0.0% | 0.00% | -100.0% |
| Q2 2021 | $8,517,000 | +15.9% | 474,765 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $7,349,000 | +26.9% | 474,765 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $5,792,000 | +35.8% | 474,765 | +43.0% | 0.00% | – |
| Q3 2020 | $4,265,000 | – | 331,908 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lion Point Capital, LP | 3,629,622 | $33,936,000 | 7.88% |
| VR Adviser, LLC | 3,156,803 | $29,516,000 | 4.78% |
| Bleichroeder LP | 1,322,463 | $12,365,000 | 2.19% |
| Bain Capital Life Sciences Investors, LLC | 1,431,058 | $13,380,000 | 1.30% |
| 683 Capital Management, LLC | 1,932,829 | $18,072,000 | 0.97% |
| Granite Point Capital Management, L.P. | 472,056 | $4,414,000 | 0.92% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 2,766,000 | $25,862,000 | 0.79% |
| Avoro Capital Advisors LLC | 3,150,000 | $29,453,000 | 0.54% |
| Artal Group S.A. | 1,000,000 | $9,350,000 | 0.39% |
| Stonepine Capital Management, LLC | 56,747 | $531,000 | 0.22% |